Dx Dialogues: Agitation in Alzheimer's Disease

Agitation in Alzheimer’s disease encompasses a heterogeneous spectrum of behaviors including verbal outbursts, physical aggression, restlessness, and resistance to care. Standardized assessment frameworks have evolved to support systematic characterization of agitation severity, temporal patterns, and potential precipitating factors.¹ The International Psychogeriatric Association has established consensus criteria that distinguish agitation from other neuropsychiatric manifestations, emphasizing the presence of excessive motor activity, verbal aggression, or physical aggression occurring with excess distress or disability beyond what is caused by the cognitive impairment.¹ Application of these criteria facilitates consistent identification and enables clinicians to differentiate agitation requiring pharmacologic intervention from behaviors better addressed through environmental modification or caregiver education.^1,2

Comprehensive evaluation of agitation necessitates consideration of medical, environmental, and psychosocial contributors that may precipitate or exacerbate symptoms. Unrecognized pain, medication side effects, infection, metabolic disturbances, and sleep disruption represent common but potentially reversible triggers.³ Structured assessment tools including the Cohen-Mansfield Agitation Inventory (CMAI) and the Neuro-Psychiatric Inventory (NPI) provide quantitative measures of symptom frequency, severity, and caregiver distress. These instruments support baseline documentation, treatment response monitoring, and longitudinal tracking of symptom evolution.³

Nonpharmacologic interventions represent the historical foundation of agitation management across all disease stages.² Environmental modifications addressing noise, lighting, and spatial orientation can reduce situational triggers. Music therapy, structured activities, and sensory interventions demonstrate efficacy in managing mild to moderate symptoms.² Caregiver training focused on exploring causes of stress, tangible planning for modifying environments and routines, and identifying symptom duration and frequently has been shown to reduce caregiver burden and reduce behavioral symptoms in patients.⁴

When nonpharmacologic strategies prove insufficient, pharmacologic interventions targeting specific neurotransmitter systems offer additional therapeutic options. Brexpiprazole, a noradrenergic α_1B and α_2C and serotonergic 5-HT2A receptor antagonist and partial agonist at 5-HT1A and dopaminergic D2 receptors, addresses the neurobiological dysfunction underlying agitation.⁵ It also has FDA approval for schizophrenia and major depressive disorder in adults. It is important to note that brexpiprazole carries a boxed warning for increased mortality in elderly patients with dementia and for suicidal thoughts and behaviors.⁶ Atypical antipsychotics represent historic alternative options, though selection must account for individual patient factors including cardiovascular risk, extrapyramidal symptoms, metabolic considerations, and concurrent medications.⁷ Traditional sedative approaches including benzodiazepines carry substantial risks including cognitive worsening, falls, paradoxical disinhibition, and increased mortality particularly among nursing home residents with dementia in hospice care, necessitating careful consideration of disease stage and clinical context when weighing potential symptomatic benefits against safety concerns.⁸

Clinical decision-making incorporates assessment of symptom severity, functional impairment, safety concerns, prior treatment responses, and patient-specific risk factors. Collaboration with caregivers regarding treatment goals, expected timelines for response, potential adverse effects, and criteria for reassessment establishes shared understanding and facilitates ongoing monitoring. Documentation of specific target symptoms enables objective evaluation of treatment efficacy and supports systematic titration or discontinuation strategies based on individual response patterns.

Take our agitation in Alzheimer’s disease quiz to see how your knowledge compares to your peers.